GT919

**GT919** is an oral molecular glue degrader developed by Gluetacs Therapeutics that selectively targets IKZF3 (Aiolos) and IKZF1 (Ikaros) transcription factors by recruiting them to the CRBN E3 ubiquitin ligase for proteasomal degradation. It exhibits potent degradation at low nanomolar concentrations, delivering dual antitumor and immunomodulatory effects in lenalidomide- or pomalidomide-refractory multiple myeloma models. GT919 demonstrates superior selectivity, potency, safety (with transient hematologic toxicities), bone marrow lesion enrichment, and blood-brain barrier penetration compared to competitors like CC-92480, positioning it as a differentiated candidate for hematologic malignancies.[1][2][3]